-
1Academic Journal
Source: Клиническая онкогематология, Vol 18, Iss 1 (2025)
-
2Academic Journal
Source: Клиническая онкогематология, Vol 16, Iss 3 (2024)
-
3Academic Journal
Source: Клиническая онкогематология, Vol 15, Iss 3 (2022)
-
4Academic Journal
Authors: Larisa Girshova, T. Chitanava, Konstantin Bogdanov, TS Nikulina, AYu Zaritskey, VV Ivanov, YuV Mirolyubova, YuA Alekseeva, RSh Badaev, NA Zhukova, D.V. Zaitsev, KA Zagorodnikova, S.V. Efremova, Irina Budaeva, Dmitry Motorin
Source: Клиническая онкогематология, Vol 13, Iss 1 (2020)
Subject Terms: гемтузумаб озогамицин, острые миелоидные лейкозы, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, пациенты в критическом состоянии, рефрактерное течение, RC254-282, 3. Good health
-
5Academic Journal
Authors: M. S. Korneeva, N. A. Batmanova, T. T. Valiev, K. I. Kirgizov, М. С. Корнеева, Н. А. Батманова, Т. Т. Валиев, К. И. Киргизов
Source: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 2 (2023); 92-98 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 2 (2023); 92-98 ; 2413-5496 ; 2311-1267
Subject Terms: дети, relapse, refractory course, treatment, children, рецидив, рефрактерное течение, лечение
File Description: application/pdf
Relation: https://journal.nodgo.org/jour/article/view/940/827; Karis J., Bernstrand C., Fadeel B., Henter J.-I. The incidence of langerhans cell histiocytosis in children in Stockholm Count, Sweden 1992–2001. In: Proceedings of the XIX meeting of the histiocyte society. Philadelphia, 2003. P. 21.; Monsereenusorn C., Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29:853–73. doi:10.1016/j.hoc.2015.06.005.; Haupt R., Minkov M., Astigarraga I., Schäfer E., Nanduri V., Jubran R., Egeler R.M., Janka G., Micic D., Rodriguez-Galindo C., Van Gool S., Visser J., Weitzman S., Donadieu J.; Euro Histio Network. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–84. doi:10.1002/pbc.24367.; Gadner H., Grois N., Arico M., Broadbent V., Ceci A., Jakobson A., Komp D., Michaelis J., Nicholson S., Pötschger U., Pritchard J., Ladisch S.; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138:728–34. doi:10.1067/mpd.2001.111331.; Gadner H., Grois N., Potschger U., Minkov M., Aricò M., Braier J., Broadbent V., Donadieu J., Henter J.-I., McCarter R., Ladisch S.; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensifi cation. Blood. 2007;111:2556–62. doi:10.1182/blood-2007-08-106211.; Minkov M., Grois N., Heitger A., Pötschger U., Westermeier T., Gadner H.; DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol. 2002;39:581–5. doi:10.1002/mpo.10166.; Ronceray L., Potschger U., Janka G., Gadner H., Minkov M.; German Society for Pediatric Hematology and Oncology, Langerhans Cell Histiocytosis Study Group. Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: Eff ect on course and outcome. J Pediatr. 2012;161:129–33. doi:10.1016/j.jpeds.2011.12.035.; Braier J., Latella A., Balancini B., Castaños C., Rosso D., Chantada G., Ripoli M., Goldberg J. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:765–9. doi:10.1002/pbc.20112.; Евсеев Д.А., Калинина И.И., Ускова Н.Г., Самарин А.Е., Райкина Е.В., Салимова Т.Ю., Байдильдина Д.Д., Горонкова О.В., Митрофанова А.М., Масчан М.А., Масчан А.А. Применение превентивного плевродеза у пациента с гистиоцитозом из клеток Лангерганса с поражением легких. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(3):74‒80. doi:10.24287/1726-1708-2018-17-3-74-80.; Weitzman S., Egeler R.M. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008;20:23–9. doi:10.1097/MOP.0b013e3282f45ba4.; Donadieu J., Chalard F., Jeziorski E. Medical management of Langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13:1309–22. doi:10.1517/14656566.2012.688028.; Satter E.K., High W.A. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008;25:291–5. doi:10.1111/j.1525-1470.2008.00669.x.; Grifo A.H. Langerhans cell histiocytosis in children. J Pediatr Oncol Nurs. 2009;26:41–7. doi:10.1177/1043454208323915.; McClain K.L. Treatment of Langerhans cell histiocytosis. In: Post TW, editor. Up To Date. Waltham, MA. Accessed 22 June 2019.; Gadner H., Minkov M., Grois N., Pötschger U., Thiem E., Aricò M., Astigarraga I., Braier J., Donadieu J., Henter J.-I., Janka-Schaub G., McClain K.L., Weitzman S., Windebank K., Ladisch S.; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14. doi:10.1182/blood-2012-09-455774.; Cui L., Wang C.J., Lian H.Y., Zhang L., Ma H.H., Wang D., Chen F.F., Zhang Q., Yang Y., Wei A., Huang X.T., Zhu T., Wang T.Y., Li Z.G., Zhang R. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study. Am J Hematol. 2023;98(4):598–607. doi:10.1002/ajh.26829.; Donadieu J., Bernard F., van Noesel M., Barkaoui M., Bardet O., Mura R., Arico M., Piguet C., Gandemer V., Armari Alla C., Clausen N., Jeziorski E., Lambilliote A., Weitzman S., Henter J.I., Van Den Bos C.; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study. Blood. 2015;126:1415–23. doi:10.1182/blood-2015-03-635151.; Veys P.A., Nanduri V., Baker K.S., He W., Bandini G., Biondi A., Dalissier A., Davis J.H., Eames G.M., Egeler R.M., Filipovich A.H., Fischer A., Jürgens H., Krance R., Lanino E., Leung W.H., Matthes S., Michel G., Orchard P.J., Pieczonka A., Ringdén O., Schlegel P.G., Sirvent A., Vettenranta K., Eapen M. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning. Br J Haematol. 2015;169:711–8. doi:10.1111/bjh.13347.; Bernard F., Thomas C., Bernard Y., Munzer M., Parker J.L., Ouache M., Colin V.M., Perel Y., Chastagner P., Vermylen C., Donadieu J. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with hematological dysfunction. Eur J Cancer. 2005;41:2682–9. doi:10.1016/j.ejca.2005.02.007.; Steinherz P.G., Meyers P.A., Steinherz L.J., Jeha S. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol. 2007;29:656–8. doi:10.1097/MPH.0b013e318142b94b.; Abraham А., Alsultan А., Jeng М., Rodriguez-Galindo С., Campbell Р.К. Clofarabine Salvage Therapy for Refractory High-Risk Langerhans Cell Histiocytosis. Pediatr Blood Cancer 2013;60:e19–22. doi:10.1002/pbc.24436.; Berres M.L., Lim K.P., Peters T., Price J., Takizawa H., Salmon H., Idoyaga J., Ruzo A., Lupo P.J., Hicks M.J., Shih A., Simko S.J., Abhyankar H., Chakraborty R., Leboeuf M., Beltrão M., Lira S.A., Heym K.M., Bigley V., Collin M., Manz M.G., McClain K., Merad M., Allen C.E. BRAF-V600E expression in precursor versus diff erentiated dendritic cells defi nes clinically distinct LCH risk groups. J Exp Med. 2014;211:669–83. doi:10.1084/jem.20130977.; Badalian-Very G., Vergilio J.A., Degar B.A., MacConaill L.E., Brandner B., Calicchio M.L., Kuo F.C., Ligon A.H., Stevenson K.E., Kehoe S.M., Garraway L.A., Hahn W.C., Meyerson M., Fleming M.D., Rollins B.J. Recurrent BRAF Mutations in Langerhans Cell Histiocytosis. Blood 2010;116(11):1919–23. doi:10.1182/blood-2010-04-279083.; Chakraborty R., Hampton O.A., Shen X., Simko S.J., Shih A., Abhyankar H., Lim K.P.H., Covington K.R., Trevino L., Dewal N., Muzny D.M., Doddapaneni H., Hu J., Wang L., Lupo P.J., Hicks M.J., Bonilla D.L., Dwyer K.C., Berres M.-L., Poulikakos P.I., Merad M., McClain K.L., Wheeler D.A., Allen C.E., Parsons D.W. Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. Blood 2014;124(19):3007–15. doi:10.1182/blood-2014-05-577825.; Heritier S., Emile J.F., Barkaoui M.A., Thomas C., Fraitag S., Boudjemaa S., Renaud F., Moreau A., Peuchmaur M., Chassagne-Clément C., Dijoud F., Rigau V., Moshous D., Lambilliotte A., Mazingue F., Kebaili K., Miron J., Jeziorski E., Plat G., Aladjidi N., Ferster A., Pacquement H., Galambrun C., Brugières L., Leverger G., Mansuy L., Paillard C., Deville A., Armari-Alla C., Lutun A., Gillibert-Yvert M., Stephan J.-L., Cohen-Aubart F., Haroche J., Pellier I., Millot F., Lescoeur B., Gandemer V., Bodemer C., Lacave R., HéliasRodzewicz Z., Taly V., Geissmann F., Donadieu J. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to fi rst-line therapy. J Clin Oncol. 2016;34:3023–30. doi:10.1200/JCO.2015.65.9508.; Donadieu J., Larabi I.A., Tardieu M., Visser J., Hutter C., Sieni E., Kabbara N., Barkaoui M., Miron J., Chalard F., Milne P., Haroche J., Cohen F., Hélias-Rodzewicz Z., Simon N., Jehanne M., Kolenova A., Pagnier A., Aladjidi N., Schneider P., Plat G., Lutun A., Sonntagbauer A., Lehrnbecher T., Ferster A., Efremova V., Ahlmann M., Blanc L., Nicholson J., Lambilliote A., Boudiaf H., Lissat A., Svojgr K., Bernard F., Elitzur S., Golan M., Evseev D., Maschan M., Idbaih A., Slater O., Minkov M., Taly V., Collin M., Alvarez J.C., Emile J.F., Héritier S. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31):2857–65. doi:10.1200/JCO.19.00456.; Brown N.A., Furtado L.V., Betz B.L., Kiel M.J., Weigelin H.C., Lim M.S., Elenitoba-Johnson K.S.J. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655–8. doi:10.1182/blood-2014-05-577361.; Greaves W.O., Verma S., Patel K.P., Davies M.A., Barkoh B.A., Galbincea J.M., Yao H., Lazar A.J., Aldape K.D., Medeiros L.J., Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn. 2013;15(2):220–6. doi:10.1016/j.jmoldx.2012.10.002.; Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., Dicara D., Ramos A.H., Lawrence M.S., Cibulskis K., Sivachenko A., Voet D., Saksena G., Stransky N., Onofrio R.C., Winckler W., Ardlie K., Wagle N., Wargo J., Chong K., Morton D.L., Stemke-Hale K., Chen G., Noble M., Meyerson M., Ladbury J.E., Davies M.A., Gershenwald J.E., Wagner S.N., Hoon D.S.B., Schadendorf D., Lander E.S., Gabriel S.B., Getz G., Garraway L.A., Chin L. A Landscape of Driver Mutations in Melanoma. Cell. 2012;150(2):251–63. doi:10.1016/j.cell.2012.06.024.; Yang S., Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–7. doi:10.3892/ol.2017.5557.; Se W.L., Mukherjee J. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. In: Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics and Immunotherapy, 2018. Pp. 323–332. doi:10.1016/b978-0-12-812100-9.00022-x.; Yaeger R., Corcoran R.B. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–41. doi:10.1158/2159-8290.CD-18-1321.; Бурцев Е.А., Бронин Г.О. МЕК-ингибиторы в терапии гистиоцитоза из клеток Лангерганса. Российский журнал детской гематологии и онкологии. 2022;9(3):42–7. doi:10.21682/2311-1267-2022-9-3-42-47.; Simko S.J., Tran H.D., Jones J., Bilgi M., Beaupin L.K., Coulter D., Garrington T., McCavit T.L., Moore C., Rivera-Ortegón F., Shaff er L., Stork L., Turcotte L., Welsh E.C., Hicks M.J., McClain K.L., Allen C.E. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai–Dorfman disease. Pediatr Blood Cancer. 2014;61:479–87. doi:10.1002/pbc.24772.; https://journal.nodgo.org/jour/article/view/940
-
6Academic Journal
Authors: Kit O.I., Kamaeva I.A., Lysenko I.B., Novikova I.A., Timoshkina N.N., Nikolaeva N.V., Gaisultanova Y.S., Khamaneva N.Y., Pushkin A.A.
Source: Advances in Molecular Oncology; Vol 9, No 2 (2022); 105-110 ; Успехи молекулярной онкологии; Vol 9, No 2 (2022); 105-110 ; 2413-3787 ; 2313-805X
Subject Terms: primary mediastinal large B-cell lymphoma, targeted next-generation sequencing, primary refractory disease, первичная медиастинальная В-крупноклеточная лимфома, таргетное секвенирование нового поколения, первично рефрактерное течение заболевания
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/444/266; https://umo.abvpress.ru/jour/article/view/444
-
7Academic Journal
Source: Клиническая онкогематология, Vol 7, Iss 2 (2014)
-
8Academic Journal
Authors: Айдагулова, С., Нурланбаева, А., Гусаревич, А., Фурсова, А., Гусаревич, О.
File Description: text/html
-
9Academic Journal
Authors: Шкляев, С., Павлов, В.
Subject Terms: ЛИМФОМА ХОДЖКИНА, HODGKIN'S LYMPHOMA, РЕЦИДИВ, РЕФРАКТЕРНОЕ ТЕЧЕНИЕ, ЛЕЧЕНИЕ, БЕНДАМУСТИН
File Description: text/html
-
10Academic Journal
Source: Фундаментальные исследования.
File Description: text/html
-
11Academic Journal
Source: Клиническая онкогематология. Фундаментальные исследования и клиническая практика.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ЛИМФОМА ХОДЖКИНА, HODGKIN'S LYMPHOMA, РЕЦИДИВ, РЕФРАКТЕРНОЕ ТЕЧЕНИЕ, ЛЕЧЕНИЕ, БЕНДАМУСТИН, 3. Good health
File Description: text/html
